High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial

Autores de IIS La Fe

• 

  Javier De La Rubia Comos

  Autor

Participantes ajenos a IIS La Fe

• Lahuerta J.J.
• San-Miguel J.
• Jiménez-Ubieto A.
• Alonso R.
• Paiva B.
• Puig N.
• Cedena M.T.
• Gutierrez N.C.
• Calasanz M.J.
• Fernández Guijarro M.
• Tamayo R.R.
• Rocafiguera A.O.
• Blanchard M.J.
• Carrillo Cruz E.
• Martínez-Martínez R.
• Bargay J.
• Sureda Balari A.
• Hernández García M.T.
• Cabañas V.
• Montero F.C.
• Bernal L.P.
• Montes Y.G.
• Martínez-Lopez J.
• Rodriguez-Otero P.
• Krisnik I.
• Arguiñano J.M.
• Gonzalez García M.E.
• Ocio E.M.
• Cruz J.D.L.
• Mateos M.V.
• Rosiñol L.
• Bladé J.

Grupos

• Hematología y Hemoterapia

Abstract

Abstract no disponible

Keywords

• alanine aminotransferase; aspartate aminotransferase; bortezomib; busulfan; calcium; CD34 antigen; dexamethasone; ixazomib; lenalidomide; low molecular weight heparin; melphalan; adult; alanine aminotransferase blood level; Article; aspartate aminotransferase blood level; autologous stem cell transplantation; bacteremia; breast cancer; calcium blood level; cancer staging; cancer survival; cell count; central nervous system cancer; controlled study; demographics; drug efficacy; drug megadose; drug withdrawal; ECOG Performance Status; female; follow up; gastrointestinal cancer; gastrointestinal toxicity; genetics; high risk patient; human; infection; liver toxicity; liver venoocclusive disease; lung cancer; maintenance therapy; major clinical study; male; minimal residual disease; mucosa inflammation; multiple myeloma; myelodysplastic syndrome; neutropenia; non melanoma skin cancer; non-Hodgkin lymphoma; open study; overall survival; peripheral neuropathy; phase 3 clinical trial; progres